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INTRODUCTION 
Microalbuminuria though a relevant screening tool outside, rarely reported 
with very sparse literature in our setting.Dipstick analysis is a useful tool in 
screening of urinary abnormalities ,as itt detects hematuria,protenuria,specific 
gravity,leukocyturia.Microalbuminuria is defined as  the urinary albumin excretion 
rate of 30-300mg/dl or 20-200microgram/dl n a randomly collected urine sample. 
Microalbuminuria is said to be an indicator of widespread vascular endothelial 
damage and it reflects the transcapillary leakage of albumin. 
It has been described to be a major factor in the causation of cardiovascular 
.renal,peripheral vascular disease and cerebrovascular  diseases,especially when 
associated with conditions with Diabetes Mellitus,Systemic Hypertension.The 
prevalence ,progression and regression of microalbumnuria in these diseases  was 
studied and landmark trials have confirmed its significance.Apart from these 
conditions it has also been proved to be important in other conditions like 
malignancy,meningitis where it acts as an important prognostic marker. 
In this study we have made an attempt to find out the relation between 
microalbuminuria and stroke and an association has been found due to its relation 
with atherosclerosis responsible for the thickness in the intima and media of the 
carotid  artery. 
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REVIEW OF LITERATURE 
 
Microalbuminuria is defined as an excretion of albumin between 30-
300mg/24 hrs or 20-200micrograms/minute.Among the modifiable risk factors 
causing microalbminuria are diabetes, hypertension, obesity, smoking 
,hyperlipidemia, high salt or protein diet,oral contraceptives or hormone 
replacement  therapy. Among the non-modifiable risk factors are race/ethnicity, 
male gender, older age and low birth weight. The mechanism responsible for this is 
the abnormal permeability of the glomerulus to albumin.KDIGO has replaced this 
term microalbuminuria with the term moderately increased albuminuria.2-3 
measurements over a 2-3 month period is necessary to make a diagnosis of 
microalbuminuria. 
To overcome the variations in calculating in the spot-check samples ,amount of 
albumin in the urine against the concentration  gradient is used.Hence ,an 
albumin/creatitine ratio measured as >3.5 mg/mmol in males or >2.5mg/mmol n 
females equals 30-300mg/24 hrs. 
An early morning sample is preferred as the patient must refrain from heavy 
exercise 24 hours before the test. 
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It has been used as a prognostic marker of kidney disease in 
1.post-streptococcal  glomerulonephritis 
2.diabetes mellitus 
3.Systemic hypertension 
4.In intensive care setting it can be used as an indicator of overall mortality 
,multiorgan dysfunction and acute respiratory failure if it s seen rising after 24 
hours of admission. 
5.It is also used as a risk factor for venous thromboembolism. 
6.It is said to be a prognostic  marker in meningitis,malignancy,hypertension.Also 
found useful in assessing response in diabetes,unilateral nephrectomy or renal 
scarring. 
7.It has also found to be an indicator of glomerular injury,particularly in patients 
with sickle cell anemia prone to nephropathy.In sickle cell nephropathy,structural 
and functional abnormalities including hypoasthenuria,proteinuria with or without 
nephrotic syndrome,incomplete distal renal tubular acidosis,immune complex 
glomerulonephritis and progressive renal failure.The renal manifesations occur due 
to the microvascular occlusion of the renal vasculature by the sickle 
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cells,particularly in the absence of collateral circulation due to factors like 
hypoxia,acidosis and hypertonicity. 
8.There has also said an inverse relation between low birth weight and 
microalbuminuria stating that factors in utero or in early childhood also claim to 
cause albumnuria in adult life. 
 
Microalbuminuria and Chronic Kidney Disease 
In diabetic and the non-diabetic population,microalbuminuria or proteinuria is 
associated  with  CKD. Heavy proteinuria is associated with a faster rate of  
progression to CKD.Is has been posutalated  that those treated with  antiproteinuric 
drugs  like ACE inhibitors  or ARBs are benefitted as the rate of progression to 
CKD is retarded.The tendency for natural  progression is high when the proteinuria 
exceeds 1g/dl. 
There is an independent association between rate os urine albumin excretion and 
presence and severity of CVD,including the non-diabetic and non-hypertensive 
population. 
The common pathway linking microalbuminuria to CKD or CVD is diffuse 
endothelial and vascular dysfunction. 
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Renin Angotensin Aldosterone System has been implicated to be the common links 
between systemic hypertension,proteinuria/microalbuminuria and CVD. 
An important single predictor of GFR decline is proteinuria and hence therapies 
that reduce proteinuria is helpful n decreasing GFR. 
It has been proved from The Modification Of Diet (MDRD) and Ramipril Efficacy 
In Nephropathy (REIN) that by reducing the proteinuria to less than 1g/day there 
has been a signficant  decline in GFR from 4-10 ml/min/year to 1-2ml/min/year 
The recommended time interval for testing for proteinuria is 2-3 months for those  
with nephrotic range proteinuria and 6 months for those with  subnephrotic range 
proteinuria. 
Current guidelines suggest low-blood pressure goal is required only for those with 
greater proteinuria although lowering the blood pressure will help to lower the rate 
of proteinuria   and might probably reduce the further cardiovascular risk. 
Drugs useful in retarding proteinuria are 
1.ACE inhibitors 
2.ARBs.ACE inhibitors may be added to ARBs. 
3.Renin Inhibitor. 
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Rationale behind this is that dual therapy  will help to help to bring about the effect 
by optimizing the antiproteinuric effect through RAAS blockade. 
However this dual therapy may not help to reduce the  cardiovascular risk as  does 
either of the drugs alone.This has been proved by the ONTARGET(ongoing 
Telamsartan alone and in combination with Ramipril Global Endpoint Trial). 
Even in cases of resistant hypertension,non-dihydropyridines are recommended if 
adequate RAAS is present or eGFR<30ml as non –DHP have antihypertensive and 
antiproteinuric effects in contrast to dihydropyridines which might cause 
proteinuria. 
There has been studies revealing analysis of Losartan used in treament of 
microalbminuria and hyperentension.A study called LIFE(losartan intervention for 
endpoint reduction in hypertension) was done for patients detected to  high blood 
pressure (160-200/95) and an electrocardiographic evidence of left ventricular 
hypertrophy using a cut-off vale of > or equal to 3.5mg/mmol. Showed a 
prevalence of 26%. 
It has been proved in many studies that those with metabolic syndrome (those with 
smoking,obesity,and insulin resistance) as satisfying the criteria by Adult Treament 
Panel III had  higher range of microalbumnuria and left ventricular hypertrophy 
when compared to those without. 
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A higher the components of metabolic syndrome, more would be the prevalence of 
microalbuminuria   and higher would be the target end organ  damage. 
C-reactive protein is also a sensitive marker of inflammation and a good indicator 
of cardiovascular outcome. 
An increasing concentration of CRP from 0.2 -10mg/dl resulted in a marked 
steepening of the curve between albuminuria and arterial pressure with a 
potentiating effect when the mean arterial pressure are above 90mmHg. 
Studies have also proven that in patients with essential hypertension there has been 
no detectable decrease in glomerular filtration rate among the normoalbminurics 
and microalbuminurics.The administration of  captopril did not bring about the 
vasodialatory response in microalbminuric patients,which suggested that 
microalbminuria was an early marker of intra-renal vascular dysfunction. 
A study called Hoorn study was done to find out the risk of microalbuminuria as a 
marker for atherosclerosis,which showed that an albumin/creatinine ratio of more 
than 2mg/mmol ad peripheral arterial disease ,which was analysed by the ankle-
brachial index were associated with a fourfold increase in cardiovascular mortality 
that was more in hypertensive than in non-hypertensive population. 
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Evidence also proves that there is a greater cardiovascular morality among the 
patients  with higher microalbuminuria among the diabetic population.In the 
PREVEND international trial those who were treated with fosinopril had a much 
lesser degree of coronary events,as much as 40 percent, when compared with those 
who were not treated. 
Statins,renin inhibitors and glycosaminoglycans had also showed a reduction in 
microalbuminuria. 
 
Studies have also shown that there is a tendency for higher body mass index,lesser 
reduction in blood pressure and a greater increase in glucose and uric acic acid in 
albuminuria progressors.Population studies did not reveal any relation between 
GFR(glomerular filtration rate) and microalbuminuria., but a study called 
PREVEND(prevention of renal and vascular end-stage disease),estimation of GFR 
by 24-hour creatinine clearance tended to be higher n those with higher 
albuminuria whereas reduction in creatinine clearance was associated with 
macroalbumnuria for that age and sex. 
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CEREBROVASCULAR DISEASES 
Defined as an abrupt onset of a focal neurological deficit.It is common among the 
elderly population and its  incidence increases with age.It includes some of the 
common disorders namely, ischemic stroke,hemorrhagic stroke,anomalies like 
arteriovenous malformations and intracranial aneurysms. 
Ischemic Stroke 
A decrease in cerebral blood flow causes death of the brain tissue in 4 to 10 
minutes.Death occurs in an hour if the supply reduces by 16 to 18 ml/100 g tissue 
per minute and within several hours or days if the flow reduces by <20ml/100 g 
tissue per minute.Penumbra refers to the region surrounding the core and is 
reversibly dysfunctional.Perfusion-diffusion imaging wih CT or MRI will help to 
image the penumbra. 
 
There are 2 pathways responsible for cerebral infarction 
2.apoptotic-programmed cell death. 
CAUSES OF ISCHEMIC STROKE 
It occurs either due to insitu thrombosis or due to embolus from a proximal source 
,either an artery or from the heart. 
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CAUSES 
Thrombosis 
Lacunar stroke 
Large vessel thrombosis 
Dehydration 
Embolic Occlusion 
Artery to artery 
Carotid bifurcation 
Aortic arch 
Aortic dissection 
Cardioembolic 
Atrial fibrillation 
Mural thrombus 
Myocardial infarction 
Dialated cardiomyopathy 
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Valvular lesions 
Mitral  stenosis 
Mechanical valves 
Bacterial endocarditis 
Parodoxical embolus 
Atrial septal defect 
Patent foramen ovale 
Atrial septal aneurysm 
Spontaneous echo contrast 
 
Others 
Hypercoagulable states-protein c and protein s  and antithrombin deficiency 
Antiphospholipid antibody syndrome 
Factor V leiden mutation 
TTP 
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Homocysteinemia 
DIC 
Dysproteinemia 
Nephrotic syndrome 
Oral contraceptives 
Inflammatory bowel disease 
Venous sinus thrombosis 
Stroke of undetermined origin 
Multiinfarct dementia in lacunar syndrome 
Moyamoya disease 
Fibromuscular dysplasia 
Binswanger’s subcortical arteriosclerotic encephalopathy 
Winiwarter buerger disease 
Aortic arch syndrome 
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Risk factors 
Hypertension 
Atrial fibrillation 
Diabetes 
Smoking 
Hyperlipidemia 
Carotid stenosis 
 
The normal functions of the brain is dependent on the oxygen supply and the 
glucose perfusing it.The critical threshold for the energy metabolism is maintained 
by the pH,partial pressure of oxygen and carbondioxide,cerebrovascular resistance 
and the mean arterial blood pressure.The is paralysis of autoregulation and the 
microvasculature is nonreactive to the changes occurring making it more 
permeable to protein and fluid leaks and also causing hemoconcentration and 
vascular stasis.Due to brain hypoxia,energy is depleted and hence formation of 
ATP doesn’t occur.Among the factors that increase the neuronal injury are 
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increased cytosolic leaks due to increased intracellular calcium concentration due 
to loss of activity of sodium-potassium pump,acidosis and release of free 
radicals.Other ischemia promoting factors are exposure of the vascular 
endothelium to raised homocysteine(>100micromol/l) that leads to reduced levels 
of nitric oxide,increased levels of adhesion molecules and procaogulant factors like 
thrombomodulin,protein C,tissue plasminogen activator and plasminogen activator 
inhibitor. 
A mechanism said to be responsible for this has been that at the site of 
atheromatous plaque ,endothelial injury occurs and there is attachment of platelet 
to the exposed subendothelial collagen ,at the site of which phospholipids and 
cholesterol has been released and phospholiase A2 and cycloxygenase converts to 
potent platelet aggregator thromboxane A2. 
However a well developed vascular system is present to provide collateral 
circulation to the brain even in the presence of ischemia namely the carotid and the 
vertebral arteries .An extracranial anastomosis between the cervical branches of the 
ipsilateral external carotid,subclavian,and the vertebral arteries also provides an 
anastomosis. 
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Lacunar infarcts are also common among the diabetics and hypertensives .They are 
common in the deep white matter,basal ganglia,internal capsule,cerebellum,corona 
radiata .They are 150-300mm n size. 
Internal carotid artery can also cause stroke especially in the cervical portion that is 
prone to atherosclerosis and is also a site for embolic episodes.However ,it may be 
partly offset by the anastomosis between ophthalmic and external carotid and 
partly by the superficial and the deep  anastomosis from the opposite 
side.Symptoms of confusion ,dysarthria ,dyslexia sensory symptoms with or 
without motor weakness of the opposite side  may occur. 
 
Diagnosis of stroke 
CT brain –it is important in ruling out a a hemorrhage.A CT scan in the first 6 
hours may not show any difference.It  is also useful to decide on the line of 
management whether antiplatelets  or anticoagulants.It is also helpful in 
differentiating an ischemic infarction or a cerebral hematoma from other 
simulators like tumour or a subdural hematoma.It helps to detect small infarcts 
including lacunae(0.5cm). However brainstem lacunae may be difficult to detect. 
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CT findings 
Hyperacute<12hours-normal(50-60%),hyperdense artery sign(25-
50%),obscuration of lentiform nucleus. 
Acute(12-24hours)-low density basal ganglia,loss of grey-white matter 
interface(insular ribbon sign),sulcal enhancement. 
1-7 days-mass effect.wedge-shaped low density area involving grey and white 
matter,hemorrhagement transformation,gyral enhancement. 
1-8weeks-contrast enhancement persists ,mass effect resolves. 
Months-years-encephalomalacic change,volume loss,rarely calcification. 
 
MAGNETIC RESONANCE DIFFUSION WEGHTED AND PERFUSION 
WEIGHTED IMAGING-revealed infarcts faster than the conventional  T2 
weighted  imaging did .DWI was based on the Brownian Movement Of 
Water.Acute infarcts had lower ADC(apparent diffusion coefficients )than the 
noninfarcted regions did due to the energy failure and the subsequent cytotoxic 
edema.The DWI shows the ischemic core and PWI indicates the impaired 
perfusion in the core and in the surrounding penumbra,thereby complementing the 
DWI. Hence it played a role in making an anatomic diagnosis  early and helped in 
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implementing stroke interventions  earlier in order to save the penumbra.   In 
Perfusion Weighted  imaging,the volumes of the regions with TTP (time to 
peak)delay was calculated and has been found invarious trials that those with a 
TTP  more than 6 was associated with a more lesional enlargement in the follow up 
scans between the first and the following.  MRA  with MRI helps to find out he 
extent and severity of the lesions and is helpful in taking decisions like 
thrombolytic therapy. 
Duplex sonography and transcranial Doppler studies are also helpful in evaluating 
the extra and intracranial anastomosis ,the stenotic area and the superimposed 
thromboemboli.A Digital Subtraction Angiography will be belp to detect the 
precise degree of narrowing and the collateral circulation if a surgical procedure is 
planned .It is important to carefully weigh the risk and benefits of DSA in 
comatose patients and in those with neurological deficits. 
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TREATMENT 
After  maintenance of the vital signs ,patency of the fluid,electrolytes,prevention of 
complications like seizures,aspiration,bedsores and thrombophlebitis has to be 
looked into.Ischemic tissue infarction with break of the blood brain  barrier retains 
fluid contributing to cerebral edema.By a phenomenon called “cerebral squeeze” 
the swollen tissue also squeezes on the adjacent viable neuronal tissue and may 
even herniate. Hence measures to reduce the cerebral blood pressure like judicious 
fluid restriction,osmotic diuretics like 3%mannitol and 10%glycerol is 
helpful.Blood pressure also has to be reduced.Sodium nitroprusside is often used in  
hypertensive crises (BP>240/130mm hg)however  parenteral  use of enalapril 
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,labetalol or frusemide is also advocated .In massive cerebral or cerebellar 
infarction causing  brainstem ,decompressive craniotomy may be used. 
 
SPECIFIC THERAPIES 
Atherosclerotic risk factors 
Diabetes mellitus,systemic hypertension,obesity,smoking,dyslipidemias ,family 
history of stroke,old age,oral contraceptives, hormone replacement therapies  are 
said to proven risk factors of stroke. Several trials like SPARCL(stroke prevention 
by aggressive reduction in cholesterol levels)showed that there was a considerable 
reduction in stroke in those who were suffering from TIA and the incidence of 
stroke.Another trial namely JUPITER(justification for the use of statins in 
prevention,an intervention trail evaluating Rosuvasatin)low LDL caused by 
elevated  CRP levels also benefitted from it. 
 
Antiplatelets namely aspirin,clopidogrel was commonly used.Ticlopidine was  
used earlier but now has been banned due to side-effects like reversible 
neutropenia and diarrhea. 
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Aspirin prevents the conversion of arachidonic acid to thromboxane A 
2.Dipyridamole prevents the enzyme phosphodiesterase and therefore platelet 
aggregation.Platelets also release prostacyclin which prevents the aggregation of 
platelets. 
Ticlopidine inhibits platelet aggregation by interfering with ADP induced 
transformation of glycoprotein 2b-3a receptors on the surface of the platelets. 
Anticoagulants like heparin an warfarin have also found use in strokes occuring 
due to a cardioembolic cause like atrial fibrillation.If  the patient worsens on 
anticoagulating a immediate re-evaluation has to be done with a second CT to 
ascertain the cause as to whether there is an intracranial bleed or an extension of 
the infarct. 
Heparin  should be monitored by APTT (it must be kept upto two  times the 
control).An intravenous bolus of 100 units /kg stat followed by 1000units /hour 
infusion for 24 hours must be given. Warfarin may be given to keep the INR 
between 2-3 baring in mind the complications that occur f not properly monitored. 
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THROMBOLYTIC THERAPY 
Several measures had been tried to remove the clot lysis and to enable 
recanalisation.Available thrombolyic agents are streptokinase,recombinant tissue 
plasminogen activator,urokinase. 
Several trials have been done.One  such trial was the PROACT(prolyse in acute  
cerebral thromboembolism trial).It was done to test the efficacy and recanalisation 
by giving  prokinase 6mg or placebo which was given within 6hours within the 
onset of stroke ,that was confirmed by a CT Brain. 
Recanalisation was found in middle cerebral artery better than in internal carotid or 
basilar arteries.It was not found to be superior or inferior to intravenous 
thrombolysis.In this study co-adminisration was heparin was done and was found 
that it was associated with a small risk of bleeding. 
There were trials done to estimate the use of streptokinase(1.5million units)which 
was given within 4 hours of onset of stroke .It was found to be associated with 
more incidence of hemorrhages  and bleeding and hence the trials were withheld. 
Another trial namely the European Cooperative acute stroke study was done to see 
the efficacy of r-TPA 1.1mg/kg,of which 10 percent was given as an intravenous 
bolus and the remaining within the next one hour .Those with a CT evidence of 
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diffuse cerebral swelling,effacement of the sulci,involvement of more than 
33percent of the middle cerebral artery territory or parenchymal hypodensity were 
excluded.The outcome as suggested by the Modifed Rankin Score was 2 in the 
subgroup treated with the medication which showed a better neurological outcome 
as compared with he placebo. 
 
A study namely the National Institute Of Neurological Disorders and Stroke r-tpa 
stroke study was done to evaluate the efficacy of r-tpa at a dose  of 0.9 mg /kg ,of 
which  10 percent was given as an intravenous bolus dose and the remaining over 
an hour . within 3 hours of onset of stroke.Those suffering from ataxia alone 
,dysarthria alone ,minimal weakness or sensory loss alone were excluded from the 
study as were those with other contraindications like high blood pressure 
>185/110mmhg ,prolonged prothrombin time  beyond 15 seconds or an INR>1.7, 
thrombocytopenia or an abnormal hematocrit of below 25 percent or a blood 
glucode level of either below 50 or above 200 or improving neurological 
symptoms ,seizure at the beginning of the stroke or a gastrointesinal or urinary 
bleeding  in the preceeding 21 days or a history  of recent myocardial infarction. 
However in neonates or in children the efficacy and safety of using  the 
thrombolytic therapy for acute ischemic stroke was yet to be studied. 
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Use of thrombolytic agents for other purposes in children like arterial ,right atrial 
or caval thrombosis, in pulmonary embolism,in Blalock-Taussig shunt ,in 
thrombosed dialysis shunts and in cerebral venous thrombosis  was done.The dose 
used is 0.5mg/kg in children. 
Certain precautions to be taken  before administering were that central venous 
access,arterial punctures,or insertion of nasogastric tubes within 24 hours had to be 
refrained.Indwelling catheters  should be avoided during the drug infusion till 30 
minutes after the infusion ends. 
In case bleeding occurs,the thrombolytic therapy may be stopped depending on 
whether the bleeding points can be controlled with local pressure at the arterial or 
venous sites.  
The bleeding patient’s blood should be tested for hemoglobin,,hematocrit,partial 
thromboplastin time ,INR,platelet count and fibrinogen.After crossmatching blood 
may be transfused(4 units of packed cells and 4-6 units of cryoprecipitate or fresh 
frozen plasma ). 
Endovascular mechanical thrombectomy has also gained importance these days as 
an adjunctive measure or for those in whom thrombolytics are  contraindicated. 
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One such device is MERCI (mechanical embolus removal  in cerebral 
ischemia)which has brought good results by restoring the patency within 8 hours of 
onset of then symptoms.The Penumbra Pivotal Stroke Trial is another mechanical 
device which is also FDA approved like the MERCI. 
Many scales have been used for the diagnosis 
STROKE DIAGNOSTC SCALES: 
Face Arm Speech Test 
Cincinnati Prehospital Stroke Scale 
Los Angeles Prehospital Stroke Screen 
Recognition Of Stroke In Emergency Room Scale Comparison Studies 
 
STROKE IMPAIRMENT SCALES 
National Institute Of Health Stroke Scale 
Pediatric National Institute Of Health Stroke Scale 
European Stroke Scale 
Canadian Neurological Scale 
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Scandinavian Stroke Scale 
DISABILITY SCALES 
Barthel Index 
Functional Independence Measure 
Instrumental Activities Of Daily Living 
HANDICAP SCALES 
Modified Rankin Scale 
 
 
 
1a. Level 
of 
Conscious
ness: 
 =0- Alert; keenly responsive. 
 = 1-Not alert; but arousable by minor 
stimulation to obey, answer, or respond. 
 = 2-Not alert; requires repeated 
stimulation to attend, or is obtunded and 
______ 
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requires strong or painful stimulation to 
make movements (not stereotyped). 
 = 3-Responds only with reflex motor or 
autonomic effects or totally 
unresponsive, flaccid, and areflexic. 
1b. LOC 
Questons 
 = 0-Answers both questions correctly. 
 = 1-Answers one question correctly. 
 = 2-Answers neither question correctly. 
______ 
1c. LOC 
Command
s:. 
 = 0-Performs both tasks correctly. 
 = 1-Performs one task correctly. 
 = 2-Performs neither task correctly. 
______ 
2. Best 
Gaze: 
 = 0-Normal. 
 = 1-Partial gaze palsy; gaze is abnormal 
in one or both eyes, but forced deviation 
or total gaze paresis is not present. 
 = 2-Forced deviation, or total gaze paresis 
not overcome by the oculocephalic 
maneuver. 
______ 
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3. Visual:  = o-No visual loss. 
 = 1-Partial hemianopia. 
 = 2-Complete hemianopia. 
 = 3-Bilateral hemianopia (blind including 
cortical blindness). 
______ 
4. Facial 
Palsy: 
 = 0-Normal symmetrical movements. 
 = 1-Minor paralysis (flattened nasolabial 
fold, asymmetry on smiling). 
 = 2-Partial paralysis (total or near-total 
paralysis of lower face). 
 = 3-Complete paralysis of one or both sides 
(absence of facial movement in the 
upper and lower face). 
______ 
5. Motor 
Arm: 
 = 0-No drift; limb holds 90 (or 45) degrees 
for full 10 seconds. 
 = 1--Drift; limb holds 90 (or 45) degrees, 
but drifts down before full 10 
seconds;doesn’t hit bed. 
______ 
______ 
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-ss  2.  some effort against gravity 
 = Limb cannot get to or maintain (if cued) 
90 (or 45) degrees, drifts down to bed, 
 = 3-No effort against gravity; limb falls. 
 = 4-No movement. 
N = Amputation or joint fusion, explain: 
_____________________ 
a. 5a-Left Arm 
b. 5b-Right Arm 
6. Motor 
Leg 
 = 0-No drift; leg holds 30-degree position 
for full 5  seconds. 
 = 1-Drift; leg falls by the end of the 5-
second period but does not hit bed. 
 = 2-Some effort against gravity; leg falls to 
bed by 5 seconds, but has some effort 
against gravity. 
 = 3-No effort against gravity; leg falls to 
bed immediately. 
______ 
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 = 4-No movement. 
N = Amputation or joint fusion, explain: 
________________ 
a. 5a-Left Leg 
b. 5b-Right Leg 
7.Limb   
Ataxia 
 = 0-Absent. 
 = 1-Present in one limb. 
 = 2-Present in two limbs. 
N = Amputation or joint fusion, explain: 
________________ 
______ 
8. Sensory  = 0-Normal; no sensory loss. 
 = 1-Mild-to-moderate sensory loss; patient 
feels pinprick is less sharp or is dull on 
the affected side; or there is a loss of 
superficial pain with pinprick, but 
patient is aware of being touched. 
 = 2-Severe to total sensory loss; patient is 
not aware of being touched in the face, 
______ 
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arm, and leg. 
9. Best 
Language 
 = 0-No aphasia; normal. 
 = 1-Mild-to-moderate aphasia; some 
obvious loss of fluency or facility of 
comprehension, without significant 
limitation on ideas expressed or form of 
expression. Reduction of speech and/or 
comprehension, however, makes 
conversation about provided materials 
difficult or impossible. For example, in 
conversation about provided materials, 
examiner can identify picture or naming 
card content from patient’s response. 
 = 2-Severe aphasia; all communication is 
through fragmentary expression; great 
need for inference, questioning, and 
guessing by the listener. Range of 
information that can be exchanged is 
______ 
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limited; listener carries burden of 
communication. Examiner cannot 
identify materials provided from patient 
response. 
 = 3-Mute, global aphasia; no usable speech 
or auditory comprehension. 
 
10. Dysarthria: 
 
 
 
 
 
 
 
 
 
11.Extinction and Sensory 
 = 0-normal 
 = 1-Mild-to-moderate dysarthria; patient 
slurs at least some words and, at worst, 
can be understood with some difficulty. 
 = 2-severe dysarthria; patient's speech is so 
slurred as to be unintelligible in the 
absence of or out of proportion to any 
dysphasia, or is mute/anarthric. 
N = Intubated or other physical barrier, 
explain:____ 
 
 = 0-No abnormality. 
 = 1-Visual, tactile, auditory, spatial, 
personal inattention or extinction to bilat
simultaneous stimulation in one of the sens
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Inattention modalities. 
 = 2-Profound hemi-inattention or extinction 
more than one modality; does not recogni
own hand or orients to only one side of space.
______ 
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NIHSS
• SCALE
• 0-no stroke symptoms
• 1-4-minor symptoms
• 5-15-moderate disabilty
• 16-20-moderate to severe  disability
• 21-42-severe diability. 
 
 
 
MODIFIED RANKN SCALE
• 0-no symptoms
• 1-no significant diasbility.able to carry out all usual 
activities,despite some symptoms
• 2-slight disability.able to look after own affairs without any 
assistance,but unable to carry out all previous activities.
• 3-moderate disability.requires some help but able to walk 
unassisted.
• 4-moderately severe disability.unable to attend o own 
bodily needs without assistance,and unable to walk 
unassisted.
• 5-severe disability.requires constant nursing care and 
attention.
• 6-dead
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The above is the approach towards a case of confirmed stroke,indications for 
imaging ,need for specialist care followed by stroke rehabiltation. 
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The above is the flow chart showing an approach towards a case suspected of 
having a transient ischemic attack.  
 
Rapid recognition of symptoms and diagnosis  
There is evidence that rapid treatment improves outcome after stroke or TIA. The 
recommendations in this section cover the rapid diagnosis of people who have had 
sudden onset of symptoms that are indicative of stroke and TIA. How to identify 
risk of subsequent stroke in people who have had a TIA is also covered. 
“Prompt recognition of symptoms of stroke and TIA  
In people with sudden onset of neurological symptoms a validated tool, 
such as FAST (Face Arm Speech Test), should be used outside hospital to 
screen for a diagnosis of stroke or TIA. 
In people with sudden onset of neurological symptoms, hypoglycemia 
should be excluded as the cause of these symptoms. 
People who are admitted to accident and emergency (A&E) with a 
suspected stroke or TIA should have the diagnosis established rapidly 
  
48 
using a validated tool, such as ROSIER (Recognition of Stroke in the 
Emergency Room). 
Assessment of people who have had a suspected TIA, and identifying those at 
high risk of stroke 
People who have had a suspected TIA (that is, they have no neurological 
symptoms at the time of assessment [within 24 hours]) should be assessed 
as soon as possible for their risk of subsequent stroke using a validated 
scoring system such as ABCD2.  
People who have had a suspected TIA who are at high risk of stroke (that 
is, with an ABCD2 score of 4 or above) should have: 
 aspirin (300 mg daily) started immediately 
 specialist assessment and investigation within 24 hours of onset 
of symptoms 
 measures for secondary prevention introduced as soon as the 
diagnosis is confirmed, including discussion of individual risk 
factors. 
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People with crescendo TIA (two or more TIAs in a week) should be 
treated as being at high risk of stroke, even though they may have an 
ABCD2 score of 3 or below. 
People who have had a suspected TIA who are at lower risk of stroke (that 
is, an ABCD2score of 3 or below) should have:  
 aspirin (300 mg daily) started immediately  
 specialist assessment[10] and investigation as soon as possible, 
but definitely within 1 week of onset of symptoms 
 measures for secondary prevention introduced as soon as the 
diagnosis is confirmed, including discussion of individual risk 
factors. 
People who have had a TIA but who present late (more than 1 week after their last 
symptom has resolved) should be treated as though they are at lower risk of stroke. 
Imaging in people who have had a suspected TIA or non-disabling stroke 
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While all people with symptoms of acute stroke need urgent brain scanning, there 
is less evidence to recommend brain scanning in those people whose symptoms 
have completely resolved by the time of assessment. This section contains 
recommendations about which people with suspected TIA need brain imaging and 
the type of imaging that is most helpful.  
Some people who have had a stroke or TIA have narrowing of the carotid artery 
that may require surgical intervention. Carotid imaging is required to define the 
extent of carotid artery narrowing. Sections 1.2.3 and 1.2.4 cover the optimum 
timing of carotid imaging, and the selection of appropriate patients for, and timing 
of, carotid endarterectomy. The use of carotid stenting was also reviewed by the 
GDG. However, no evidence for early carotid stenting was found on which the 
GDG felt they could base a recommendation. For more information, see chapter 6 
of the full guideline. 
Suspected TIA – referral for urgent brain imaging 
People who have had a suspected TIA (that is, whose symptoms and signs 
have completely resolved within 24 hours) should be assessed by a 
specialist (within 1 week of symptom onset) before a decision on brain 
imaging is made.  
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People who have had a suspected TIA who are at high risk of stroke (for 
example, an ABCD2 score of 4 or above, or with crescendo TIA) in whom 
the vascular territory or pathology is uncertain should undergo urgent 
brain imaging (preferably diffusion-weighted MRI [magnetic resonance 
imaging]).  
People who have had a suspected TIA who are at lower risk of stroke (for 
example, an ABCD2 score of less than 4) in whom the vascular territory 
or pathology is uncertain should undergo brain imaging (preferably 
diffusion-weighted MRI).  
Type of brain imaging for people with suspected TIA 
People who have had a suspected TIA who need brain imaging (that is, 
those in whom vascular territory or pathology is uncertain) should undergo 
diffusion-weighted MRI except where contraindicated, in which case CT 
(computed tomography) scanning should be used. 
Early carotid imaging in people with acute non-disabling stroke or TIA 
All people with suspected non-disabling stroke or TIA who after specialist 
assessment are considered as candidates for carotid endarterectomy should 
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have carotid imaging within 1 week of onset of symptoms. People who 
present more than 1 week after their last symptom of TIA has resolved 
should be managed using the lower-risk pathway. 
Specialist stroke units 
All people with suspected stroke should be admitted directly to a specialist 
acute stroke unit following initial assessment, either from the community 
or from the A&E department.  
Brain imaging for the early assessment of people with acute stroke 
Brain imaging should be performed immediately for people with acute 
stroke if any of the following apply:  
 indications for thrombolysis or early anticoagulation treatment  
 on anticoagulant treatment 
 a known bleeding tendency 
 a depressed level of consciousness (Glasgow Coma Score below 
13) 
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 unexplained progressive or fluctuating symptoms 
 papilloedema, neck stiffness or fever 
 severe headache at onset of stroke symptoms. 
For all people with acute stroke without indications for immediate brain 
imaging, scanning should be performed as soon as possible. 
Pharmacological treatments for people with acute stroke  
Urgent treatment has been shown to improve outcome in stroke. This section 
contains recommendations about urgent pharmacological treatment in people with 
acute stroke.  
Thrombolysis with alteplase 
Alteplase is recommended for the treatment of acute ischaemic stroke 
when used by physicians trained and experienced in the management of 
acute stroke. It should only be administered in centres with facilities that 
enable it to be used in full accordance with its marketing authorization. 
 Alteplase should be administered only within a well organised stroke service with: 
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 staff trained in delivering thrombolysis and in monitoring for any 
complications associated with thrombolysis 
 level 1 and level 2 nursing care staff trained in acute stroke and 
thrombolysis 
 immediate access to imaging and re-imaging, and staff trained to 
interpret the images. 
Aspirin and anticoagulant treatment 
People with acute ischaemic stroke 
All people presenting with acute stroke who have had a diagnosis of 
primary intracerebral haemorrhage excluded by brain imaging should, as 
soon as possible but certainly within 24 hours, be given:  
 aspirin 300 mg orally if they are not dysphagic or 
 aspirin 300 mg rectally or by enteral tube if they are dysphagic. 
 
Thereafter, aspirin 300 mg should be continued until 2 weeks 
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after the onset of stroke symptoms, at which time definitive long-
term antithrombotic treatment should be initiated. People being 
discharged before 2 weeks can be started on long-term treatment 
earlier.  
Any person with acute ischaemic stroke for whom previous dyspepsia 
associated with aspirin is reported should be given a proton pump inhibitor 
in addition to aspirin. 
Any person with acute ischaemic stroke who is allergic to or genuinely 
intolerant of aspirin should be given an alternative antiplatelet agent.  
Anticoagulation treatment should not be used routinely for the treatment 
of acute stroke.  
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People with acute venous stroke 
People diagnosed with cerebral venous sinus thrombosis (including those 
with secondary cerebral haemorrhage) should be given full-dose 
anticoagulation treatment (initially full-dose heparin and then warfarin 
[INR 2–3]) unless there are comorbidities that preclude its use. 
People with stroke associated with arterial dissection 
People with stroke secondary to acute arterial dissection should be treated 
with either anticoagulants or antiplatelet agents, preferably as part of a 
randomised controlled trial to compare the effects of the two treatments. 
People with acute ischaemic stroke associated with antiphospholipid 
syndrome 
People with antiphospholipid syndrome who have an acute ischaemic 
stroke should be managed in same way as people with acute ischaemic 
stroke without antiphospholipid syndrome. 
Reversal of anticoagulation treatment in people with haemorrhagic stroke 
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Clotting levels in people with a primary intracerebral haemorrhage who 
were receiving anticoagulation treatment before their stroke (and have 
elevated INR) should be returned to normal as soon as possible, by 
reversing the effects of the anticoagulation treatment using a combination 
of prothrombin complex concentrate and intravenous vitamin K. 
Anticoagulation treatment for other comorbidities  
People with disabling ischaemic stroke who are in atrial fibrillation should 
be treated with aspirin 300 mg for the first 2 weeks before considering 
anticoagulation treatment.  
In people with prosthetic valves who have disabling cerebral infarction 
and who are at significant risk of haemorrhagic transformation, 
anticoagulation treatment should be stopped for 1 week and aspirin 
300 mg substituted.  
People with ischaemic stroke and symptomatic proximal deep vein 
thrombosis or pulmonary embolism should receive anticoagulation 
treatment in preference to treatment with aspirin unless there are other 
contraindications to anticoagulation. 
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People with haemorrhagic stroke and symptomatic deep vein thrombosis 
or pulmonary embolism should have treatment to prevent the development 
of further pulmonary emboli using either anticoagulation or a caval filter. 
Statin treatment  
Immediate initiation of statin treatment is not recommended in people with 
acute stroke. 
People with acute stroke who are already receiving statins should continue 
their statin treatment. 
Maintenance or restoration of homeostasis 
A key element of care for people with acute stroke is the maintenance of cerebral 
blood flow and oxygenation to prevent further brain damage after stroke. This 
section contains recommendations on oxygen supplementation, maintenance of 
normoglycaemia, and acute blood pressure manipulation.  
Blood sugar control 
People with acute stroke should be treated to maintain a blood glucose 
concentration between 4 and 11 mmol/litre. 
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Provide optimal insulin therapy, which can be achieved by the use of 
intravenous insulin and glucose, to all adults with type 1 diabetes with 
threatened or actual stroke. Critical care and emergency departments 
should have a protocol for such management. 
Blood pressure control 
Anti-hypertensive treatment in people with acute stroke is recommended 
only if there is a hypertensive emergency with one or more of the 
following serious concomitant medical issues: 
 hypertensive encephalopathy 
 hypertensive nephropathy 
 hypertensive cardiac failure/myocardial infarction 
 aortic dissection 
 pre-eclampsia/eclampsia 
 intracerebral haemorrhage with systolic blood pressure over 
200 mmHg. 
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Blood pressure reduction to 185/110 mmHg or lower should be considered 
in people who are candidates for thrombolysis.  
Aspiration pneumonia is a complication of stroke that is associated with increased 
mortality and poor outcomes.  
In people with dysphagia, food and fluids should be given in a form that 
can be swallowed without aspiration, following specialist assessment of 
swallowing.  
The study group was divide dinto two groups those with and those without 
microalbumnuria and they have been compared in terms of 
age,gender,systolic or diastolic blood pressure,NIHSS,Modified Rankin 
Scale,LVH. 
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AIMS OF THE STUDY 
1. To estimate the prevalence of microalbuminuria in  non-diabetic acute 
ischemic stroke. 
2. To assess the stroke severity using NIHSS and MODIFIED RANKIN 
SCALE. 
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METHODS AND MATERIALS 
STUDY GROUP: 
Patients with new onset acute ischemic stroke within 24 hours of presentation 
to Kilpauk Medical College Hospital 
Study Design: 
Descriptive study  
Place of study : 
Government Kilpauk Medical College Hospital 
Period Of Study: 
December 2014-June 2015. (6 months ) 
Collaborating Departments 
The study was done with the help of Department of Biochemistry for various 
biochemical parameters and Departments of Radiology for Computed 
Tomography of brain to confirm an acute ischemic stroke. 
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Selection Of Study Subjects: 
The study subject was selected from a total of 182 patients admitted with 
acute ischemic stroke presenting within 24 hours of onset.They were carefully 
analysed for the exclusion criteria and the sample size was shrunk to 53. 
INCLUSION CRITERIA: 
The patient profile studied included both  female and male patients between 
the age group between 25-83 years admitted within 24 hours of onset of acute 
ischemic stroke as confirmed bv Computed Tomography. 
EXCLUSION CRITERIA: 
1.Positive urine analysis including hematuria,proteinuria,pyuria,glycosuria. 
2.Systemic Hypertension. 
3.Kidney diseases both congenital and acquired.  
4.Diabetes Mellitus. 
5.Liver disease  
6.Chronic inflammatory intestinal Disease. 
7.Neoplasm  
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8.Any sign of infection. 
9.Acute coronary event or Coronary artery disease. 
10.Other congenital or endocrine disorders. 
11.Inflammatory rheumatic disease. 
12.Dyslipdemia 
13.Those on NSAIDS or immunosuppresants. 
14.Fever       
Details of study subjects 
All patients at the time of admission had their history taken and underwent a 
detailed checkup. 
The severity was calculated using the NIHSS (National Institute Of Health 
Stroke Scale). 
The patient or caregiver were interviewed to establish the past medical or 
personal history. 
All patents had their blood pressure and electrocardiogram taken. 
Acute ischemic stroke was confirmed using Computed Tomography Of Brain. 
Blood glucose levels,hematocrit,WBC ,blood urea and serum creatinine and 
electrolytes and the lipid profile of the patients were taken. 
The spot urine albumin excretion was calculated and expressed in mg/dl. 
NIHSS was calculated on day 1 and Modified Rankin Scale was calculated on 
day 14 of diagnosis. 
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STUDY DETAILS 
In the study ,the subjects were divided into 2 groups ,those with 
microalbumnuria GROUP A and those without microalbuminuria-GROUP 
B. 
These two groups were compared in terms of their age,gender,systolic and 
diastolic blood pressure,ECG evidence of left ventricular 
hypertrophy,Modified Rankin Scale and NIHSS .  
 
SIGNFICANT CORELATION 
Urine Albumin Excretion and Age 
Urine albumin Excretion and Gender 
Urine albumin Excretion and NIHSS 
Urine albumin excretion and Modified Rankin Scale 
Urine albumin excretion and Left Ventricular Hypertrophy 
Urine albumin Excretion and Systolic and Diastolic blood pressure.  
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OBSERVATION AND ANALYSIS 
The study group has been divided into 2 groups 
A-patients with microalbuminuria. 
B-patients without microalbuminuria. 
The two groups have been compared on the  basis on age,gender.left 
ventricular hypertrophy,systolic and diastolic blood pressure,NIHSS and 
Modified Rankin Scale . 
 
 
Frequency Percent 
 Female 18 34.0 
Male 35 66.0 
Total 53 100.0 
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The above diagram shows that in the study there was a majority of male of 66% 
and females constituted only 34%. 
 
LVH 
  
Frequency Percent 
  
 
Valid - ve 32 60.4   
 
+ ve 21 39.6   
 
Total 53 100.0   
  
Female 
34% 
Male 
66% 
Gender Distribution 
  
68 
 
The above histogram showed that left ventricular hypertrophy was present in 
39.6% who had microalbuminuria and it was present in 60.4% of those who did 
not have microalbuminuria. 
      
 
 
0
5
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35
- ve + ve
32 
21 
LVH distribution 
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MODIFIED RANKIN SCALE 
 
Frequency Percent 
  
 No Sig. 
disability 
18 34.0   
Slight 
disabillty 
15 28.3   
Moderate 
disability 
13 24.5   
Moderate 
severe 
disability 
7 13.2   
Total 53 100.0   
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The above diagram shows that in the study group,18 suffered from no signifcant 
disability ,15 from slight disability,13 from moderate and 7 from moderate to 
severe disability. 
 
 
18 
15 
13 
7 
0
5
10
15
20
No Sig.
disability
Slight
disabillty
Moderate
disability
Moderate
severe
disability
Modified rank 
<= 30 
47% 
> 30 
53% 
UAE range 
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UAErange 
 
Frequency Percent 
  Valid <= 
30 
25 47.2   
> 30 28 52.8   
Total 53 100.0   
 
In the study group,52.8 percent were microalbumnurics,and 47.2 percent were non-
microalbuminurics 
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Age Range : 
 
 
13 
31 
9 
0
5
10
15
20
25
30
35
Upto 50 yrs 51 - 60 yrs Above 60 yrs
Age range 
   
 
 
 
Frequency Percent 
 Upto 
50 yrs 
13 24.5 
51 - 
60 yrs 
31 58.5 
Above 
60 yrs 
9 17.0 
Total 53 100.0 
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In the group,13 subjects were below 50 years of age,31 were between 51-60 
years,and 9 were above 60 years of age. 
NIHSS RANGE : 
 
 
Frequency Percent 
 Minor 9 17.0 
Moderate 27 50.9 
Moderate 
to Severe 
17 32.1 
Total 53 100.0 
 
0
5
10
15
20
25
30
Minor Moderate Moderate to
Severe
9 
27 
17 
NIHSS range 
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In the study group,9 had only minor disability,27 had moderate ,17 had moderate-
severe disability. 
 
Descriptive Statistics:  
 
N Minimum Maximum Mean 
Std. 
Deviation 
AGE 53 43 80 55.77 7.617 
SBP 53 124 176 147.92 13.020 
DBP 53 70 110 90.94 10.916 
NIHSS 53 1 20 10.79 5.415 
UAE 53 6 184 54.91 47.126 
 53     
       
      GENDER = Female 
   
      Descriptive Statisticsa 
 
N Minimum Maximum Mean 
Std. 
Deviation 
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AGE 18 45 80 58.22 9.687 
 18     
 GENDER = Female  
 
N Minimum Maximum Mean 
Std. 
Deviation 
AGE 35 43 70 54.51 6.085 
  35     
a. GENDER = Male 
He mean age among the female population was 58.22 with a standard deviation 
of 9.687.and among the male population was 54.51 with a standard deviation of 
6.085. 
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NIHSSrange vs UAErange 
  
      
 
 
UAErange 
Total <= 30 > 30 
NIHSSrange Minor Count 8 1 9 
% within 
UAErange 
32.0% 3.6% 17.0% 
Moderate Count 16 11 27 
% within 
UAErange 
64.0% 39.3% 50.9% 
Moderate 
to Severe 
Count 1 16 17 
% within 
UAErange 
4.0% 57.1% 32.1% 
Total Count 25 28 53 
% within 
UAErange 
100.0% 100.0% 100.0% 
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<= 30 > 30 
Minor 8 1 
Moderate 16 11 
Moderate 
to Severe 
1 16 
   
   
   
 
From the above study 8 among the non-microalbumnurics and 1 microalbumnuric 
suffered from minor disability.16 among the non-microalbumnurics and 11 
microalbumnurics suffered from moderate and 1 from non-microalbummuric and 
16 from microalbumnuric suffered from severe disability.This shows a statistically 
significant relation exists between NIHSS and urine albumin excretion with a p 
value of .000 
8 
16 
1 1 
11 
16 
0
2
4
6
8
10
12
14
16
18
Minor Moderate Moderate to Severe
NIHSSrange with UAErange 
<= 30 > 30
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UAErange 
Total <= 30 > 30 
MODIFIED 
RANKIN 
No Sig. 
disability 
Count 15 3 18 
% within 
UAErange 
60.0% 10.7% 34.0% 
Slight 
disabillty 
Count 6 9 15 
% within 
UAErange 
24.0% 32.1% 28.3% 
Moderate 
disability 
Count 4 9 13 
% within 
UAErange 
16.0% 32.1% 24.5% 
Moderate 
severe 
disability 
Count 0 7 7 
% within 
UAErange 
0.0% 25.0% 13.2% 
Total Count 25 28 53 
% within 
UAErange 
100.0% 100.0% 100.0% 
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<= 30 > 30 
No Sig. 
disability 
15 3 
Slight 
disabillty 
6 9 
Moderate 
disability 
4 9 
Moderate 
severe 
disability 
0 7 
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The above table shows that a statistical significance exists between modified 
Rankin Scale and urine albumin excretion with a p value of .001.  
 
 
 
 
 
 
 
 
 
 
 
   
0
5
10
15
No Sig.
disability
Slight
disabillty
Moderate
disability
Moderate
severe
disability
MODIFIED RANK with UAErange 
<= 30 > 30
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LVH vs UAE range : 
      
 
 
UAErange 
Total <= 30 > 30 
LVH - ve Count 18 14 32 
% within 
UAErange 
72.0% 50.0% 60.4% 
+ ve Count 7 14 21 
% within 
UAErange 
28.0% 50.0% 39.6% 
Total Count 25 28 53 
% within 
UAErange 
100.0% 100.0% 100.0% 
 
 
 
 
<= 30 > 30 
- ve 18 14 
+ ve 7 14 
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From the above diagram it is evident that no significant relation exists between left 
ventricular hypertrophy and urine albumin excretion with a p value of only .102 
 
 
 
 
 
 
 
 
 
 
   
0
5
10
15
20
<= 30 > 30
LVH with UAErange 
- ve + ve
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GENDER vs UAErange 
      
 
 
UAErange 
Total <= 30 > 30 
GENDER Female Count 9 9 18 
% within 
UAErange 
36.0% 32.1% 34.0% 
Male Count 16 19 35 
% within 
UAErange 
64.0% 67.9% 66.0% 
Total Count 25 28 53 
% within 
UAErange 
100.0% 100.0% 100.0% 
 
   
 
<= 30 > 30 
Female 9 9 
Male 16 19 
No statistically significant correlation exists between gender and urine albumin 
excretion with a p value of .767 
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89 
92 
88
88
89
89
90
90
91
91
92
92
93
93
<= 30 > 30
DBP 
54 
58 
52
53
54
55
56
57
58
59
<= 30 > 30
Age 
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SBP 
<= 30 146 
> 30 150 
 
DBP 
<= 30 89 
> 30 92 
 
From the above study no significant corelation exists between systolic or diastolic 
blood pressure and urine albumin excretion. 
However there was a statistically significant corelation  between age and 
microalbuminuria with a p value of .001. 
 
NIHSS 
<= 30 7 
> 30 14 
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UAE 
Male 52.1 
Female 60.3 
 
However a significant corelation exists between NIHSS and urine albumin 
excretion.  
 
 
 
 
 
 
 
 
 
 
 
 
      
 
GENDER N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
UAE Male 35 52.11 38.097 6.440 
Female 18 60.33 61.992 14.612 
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UAErange N Mean 
Std. 
Deviation 
Std. 
Error 
Mean 
AGE <= 
30 
25 53.64 5.338 1.068 
> 
30 
28 57.68 8.857 1.674 
SBP <= 
30 
25 145.76 11.537 2.307 
> 
30 
28 149.86 14.141 2.672 
DBP <= 
30 
25 89.28 12.661 2.532 
> 
30 
28 92.43 9.065 1.713 
NIHSS <= 
30 
25 7.40 4.193 .839 
> 
30 
28 13.82 4.546 .859 
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DISCUSSION 
The relation between microalbumnuria and cerebrovascular diseases has been 
studied in the west and there seems to have been an association between the two. 
This study has been undertaken to see the relevance in our population.A total of 53 
patients was taken as the sample size after applying the  exclusion criteria. 
STRENGTH OF THE STUDY 
There has been an association found between microalbuminuria and other 
conditions like systemic hypertension,diabetes mellitus and coronary artery 
diseases,But an association between microalbumnuria and cerebrovascular diseases 
without the presence of other risk factors was yet to be ascertained.So,the crux of 
the study   is to determine whether microalbuminria is individually a risk factor. 
LIMITATION OF THE STUDY 
As the study was carried out in a tertiary care centre ,it cannot be ascertained if the 
results of the study can be reproduced even in a periphery care setting. 
Another drawback of the study was that since the stroke severity grading was to be 
done in two days some patients did not respond to the study and some had died 
.Those who died were not included in the study. 
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PREVALENCE OF MICROALBUMINURIA : 
The prevalence of microalbuminuria in non-diabetic acute ischemic stroke was 
said to be 52.8percent. 
Previous studies were done to show an asssociaton between stroke and 
microalbuminuria using Glasgow coma scale and was found to be 47 percent. 
The prevalence of microalbuminuria in stroke is similar to that reported in other 
conditions like diabetes in which a prevalence of 40 percent was reported. In 
hypertensives,it was said to be present in 37percent.However the incidence is said 
to be relatively higher in causing ischemic stroke. 
PROGNOSTIC SIGNIFICANCE OF MICROALBUMINURIA 
In earlier studies relation between ischemic stroke and microalbumnuria was 
studied using the Glasgow Coma Scale and was found to be significant.It was 
found that lower score was found in those with microalbumnuria. 
Other scale used earlier was  Scandinavian Stroke Scale . Hence measurement of 
microalbuminuria was important and treatment was considered important in 
preventing strokes. 
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GENDER AND URINE ALBUMIN EXCRETION 
From the study it seems evident that there seems no relation between gender and 
urine albumin excretion is those diagnosed with acute ischemic stroke.In this study 
we had 66 percent of the individuals and 34 percent as females. 
AGE AND MICROALBUMINURIA 
Contrary to what we expected we had a higher population in the age group 
between 51-60 figuring 31.Below 50 years we had only 13 individuals and above 
61 years we had a total population of  9.The relation between albumin excretion 
and age was found to be significant with a mean age of 53 among the non 
microalbuminurics and 58 among the microalbumnurics showing a statistical 
significance.However there was a significant association has been found between 
age and microalbminuria. 
BLOOD PRESSURE AND MICROALBUMINURIA IN STROKE 
Blood pressure has always been a confounding factor in stroke because of a certain 
degree of dysautonomia at the time of stroke which cause an erroneous result 
showing a  falsely elevated or depressed  blood pressure.In this study there seems 
to be no difference between systolic or diastolic blood pressure and 
microalbuminuria qualitatively or quantitatively. Among the 
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microalbumbnurics,150 mm of hg was the mean systolic blood pressure and 146 
mm of Hg among the non-microalbminurics. 
Among the microalbmnurics,mean diastolic blood pressure was 92mm of hg and 
89 mm of Hg among the nonmicroalbumnurics.   
MICROALBMINURIA AND LEFT VENTRCULAR HYPERTROPHY 
In this study there seems to be no association between microalbuminuria and left 
ventricular hypertrophy.   
MICROALBUMINURA AND MODIFIED RANKIN SCALE 
This scale was used to fnd out the stroke severity on day 15 from the diagnosis of 
ischemic stroke.It was found that 3 among all the patients suffered from no 
significant disability,9 of them suffered from slight disability,9 from moderate and  
7 from moderate to severe  disability.Among the nonmicroalbuminrcs,15 of the 
patients had no significant disability,6  had slight disability and 4 from moderate 
disabilty.And from the study,it has been concluded that    
a significant association was found between modified rankin scale and 
microalbuminuria .    
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NIHSS AND MICROALBUMINURIA 
Among the microlalbumnurics ,1 patient suffered from minor disability,11 from 
moderate disability and 16 from moderate o severe disability.Among the 
nonmicroalbumnurics 8 suffered from minor  significant disability,16 from 
moderate disabily and 1 from moderate to severe disability. And hence from ths 
study it could be concluded that there was a statistical significance between NHSS 
and microalbuminuria. 
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CONCLUSION 
Prevalence of microalbuminuria in acute ischemic stroke was found out to be 52.8 
percent from  this study. 
Urine albumin excretion had a very significant statistical association with Modified  
Rankin Scale and a higher rate of albumin excretion was associated with higher 
score. 
Urine albumin excretion had a significant statistical corelation with NIHSS and a 
high urine albumin excretion was associated with higher score. 
 There also seemed to be  a significant association between   microalbuminuria and 
age from this study. 
No significant association was found between microalbuminuria and systolic or 
diastolic blood pressure  from this study. 
No significant association has been found between microalbuminuria and gender 
from this study . 
No significant association has been found out between microalbuminuria and left 
ventricular hypertrophy,  
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SUMMARY 
Microalbumnria has long been associated with nephropathy due to various causes 
and an early indicator of renal involvement including in conditions like malignancy 
and  sickle cell disease.This study has been shown to be significant as studies 
regarding its importance in cerebrovascular diseases has been  carried out in the 
west but far and few in our  country. Hence a study to relate is occurance in stroke 
has been studied.The sample size was chosen after applying the exclusion criteria t 
rule out other causes of microalbuminuria  and hence a direct association to find 
out the stroke severity using NIHSS scale on the day of diagnosis of the ischemic 
stroke and Modified Rankin Score on day 15 after diagnosing stroke was done.  
A comparison between urine albumin excretion and age ,systolic and diastolic 
blood pressure,gender ,left ventricular hypertrophy,NIHSS and Modifed Rankin 
was done and was found that  a statistical significance was present between 
microalbuminuria and NIHSS ,Modified Rankin. 
Hence microalbuminuria  was individually found to be a risk factor in ischemic 
stroke but studies concerning if treating microalbuminuria  would be helpful n 
preventing further strokes are yet to be reported. 
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  Further studies are required to see if microalbuminuria can be used as a predictor 
of vascular accidents of heart,brain,kidney and other disease processes where 
blood vessels are involved. 
 
 
  
97 
 
 
 
 
 
 
 
 
 
 
ANNEXURES 
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A- ABBREVIATIONS 
CT-computed tomography. 
UAE-urine albumin excretion. 
NIHSS-national institute of health stroke scale. 
MRS-modified Rankin Scale 
DWI-diffusion weighted imaging. 
PET-positron emission tomography  
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B-MASTERCHART 
 
sl 
no. name AGE GENDER SBP DBP LVH NIHSS mod.rank UAE 
1 S 62 M 164 110 + 17 3 114 
2 S 60 M 150 94 - 3 1 18 
3 A 53 M 124 70 - 16 1 86 
4 S 53 M 130 80 + 2 1 20 
5 I 52 M 164 110 + 16 3 25 
6 C 57 M 130 80 - 5 2 56 
7 D 58 M 1489 90 + 15 2 60 
8 J 51 M 138 80 - 1 1 6 
9 Y 60 M 176 98 + 17 2 104 
10 U 60 M 130 70 - 2 1 13 
11 L 54 M 170 100 + 18 4 124 
12 D 54 M 154 96 + 3 1 17 
13 K 64 M 154 100 - 4 2 18 
14 U 70 M 166 98 + 16 2 88 
15 R 60 M 140 92 - 4 2 15 
16 P 64 M 136 84 - 9 1 38 
17 A 54 M 130 80 - 12 4 71 
18 J 43 M 154 92 + 4 3 45 
19 S 57 M 170 110 + 5 2 17 
20 M 45 M 160 100 - 5 1 22 
21 G 45 M 154 90 - 16 2 40 
22 S 47 M 154 90 + 14 3 24 
23 B 45 M 150 90 - 5 1 20 
24 K 50 M 136 70 - 4 1 18 
25 S 54 M 140 92 + 17 3 54 
26 S 54 M 130 80 - 12 3 24 
27 L 56 M 140 94 + 7 3 50 
28 K 53 M 128 70 - 10 1 22 
29 M 60 M 130 80 - 17 4 100 
30 M 56 M 136 76 - 9 1 19 
31 R 48 M 154 96 + 20 4 110 
32 S 50 M 160 100 + 17 3 96 
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33 M 59 F 140 82 - 8 1 18 
34 K 60 F 154 104 + 7 1 12 
35 T 52 M 154 100 - 16 2 56 
36 S 48 F 160 110 + 7 2 7 
37 Z 50 M 148 98 - 16 4 110 
38 H 45 F 154 100 - 10 1 8 
39 I 57 M 150 96 - 18 4 124 
40 R 53 F 170 100 + 18 3 130 
41 U 49 F 140 90 - 12 1 10 
42 N 80 F 164 100 + 16 3 160 
43 R 52 F 148 96 - 12 1 12 
44 K 75 F 166 102 + 18 4 170 
45 K 54 F 138 86 - 12 2 14 
46 S 71 F 150 100 - 14 3 184 
47 J 54 F 148 98 - 14 2 90 
48 H 55 F 142 80 - 7 3 17 
49 S 50 F 130 80 - 10 3 94 
50 M 58 F 144 76 - 11 2 14 
51 K 64 F 140 86 - 7 2 48 
52 M 67 F 144 84 - 10 2 44 
53 M 54 F 156 90 + 7 1 54 
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D- PROFORMA 
Name 
Age 
Sex 
IP/OP NO: 
Marital Status: 
Educational Status: 
CLINICAL STATUS: 
Duration Of Weakness of limbs: 
c/o fever or any symptoms s/o infection: 
c/o any cardiac complaints s/o any cardiac event: 
PAST HISTORY: 
Diabetes: 
Hypertension: 
Ischemic heart disease; 
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Kidney disease,congenital or acquired: 
Liver Disease: 
Chronic inflammatory gastrointestinal disease: 
Dyslipidemia: 
Rheumatic Inflammatory disease: 
DRUG HISTORY: 
Nonsteroidal anti-inflammatory drugs: 
Immunosuppresants: 
PERSONAL HISTORY: 
Smoking: 
Alcohol: 
Diet: 
FAMLY HISTORY: 
Diabetes: 
Hypertension 
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PERSONAL  HISTORY: 
Exposure to sexually transmitted diseases: 
EXAMINATION: 
Height (metres): 
Weight(kilograms): 
Body Mass Index: 
VITAL SIGNS: 
a)Pulse rate: 
b)respiratory rate 
c)blood pressure: 
d)temperature: 
SYSTEMIC EXAMINATION: 
Cardiovascular status: 
Neurological status: 
Respiratory status: 
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INVESTIGATIONS: 
Urinealbumn,sugar,deposits: 
Blood urea: 
Serum creatinine: 
Liver function tests: 
Serum electrolytes: 
Complete hemogram : 
Chest X-Ray(Posteroanterior view): 
NIHSS SCORING(ON DAY 1): 
 SCORE 
Level of consciousness 0-3 
Horizontal eye movement 0-2 
Visual field test 0-3 
Facial palsy 0-3 
Motor arm(right and left) 0-8 
Motor leg(right and left) 0-8 
Limb ataxia 0-2 
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Sensory 02 
Language 0-3 
speech 0-2 
Extinction and inattention 0-2 
Total score 
SCORE STROKE SEVERITY 
0 No stroke symptoms 
1-4 Minor stroke 
5-15 Moderate stroke 
16-20 Moderate-severe stroke 
21-42 Severe stroke 
 
INVESTIGATIONS: 
Microalbuminuria: 
CT Brain plain: 
 
Modified rankin scale(assessed after 15 days for functional outcome): 
0-no symptoms 
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1-no significant disability.Able to carry out all ususal activities,despite some 
symptoms. 
2-slight disability.Able to look after own affairs withot assistance,but unable to 
carry out all previous activities. 
3-moderate disability.Requires some help,but able to walk unassisted. 
4-moderate to severe disability-unable to attend to own bodily needs and unable to 
walk unassisted. 
5-severe disability-Requires constant nursing care and attention,bedridden and 
incontinent. 
6-dead. 
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